Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

556
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
556
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

685
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
685
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

586
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
586
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Cancer Therapies02:49

Cancer Therapies

10.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to the letter: 'multimodality imaging in cardio-oncology: from detection to actionable management to the editor'.

European heart journal. Cardiovascular Imaging·2026
Same author

PROfessionalism in Partnership for Education Research (PROPER) study: a novel online initiative approach to professionalism education.

BMC medical education·2026
Same author

Beyond the Multidisciplinary Team: The Central Role of Nurses in Cardio-Oncology.

European journal of cardiovascular nursing·2026
Same author

External Validation of the Royal Marsden Hospital Stereotactic Radiosurgery Survival Score for Patients With Brain Metastases Treated With Stereotactic Radiosurgery.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

Quality Indicators and Benchmarks for Radiotherapy in Lung Cancer: A Modified Delphi Approach.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

Cardiovascular toxicity of breast cancer treatments: from understanding to enhancing survivorship care.

ESMO open·2025
Same journal

Curiositas - Medicine in the Kitchen.

The Ulster medical journal·2026
Same journal

Royal Victoria Hospital Annual Oration, 3rd October 2025.

The Ulster medical journal·2026
Same journal

Thrombosis and Survival after Prothrombin Complex Concentrate Use to treat Oral Anticoagulant Associated Haemorrhage.

The Ulster medical journal·2026
Same journal

Investigating Iron Deficiency Anaemia in the Elderly.

The Ulster medical journal·2026
Same journal

Avoiding Prescribing Pitfalls to Tackle Problematic Polypharmacy and Adverse Drug Reactions in Northern Ireland.

The Ulster medical journal·2026
Same journal

Sir Benjamin William Rycroft: Reflections on Character and Career.

The Ulster medical journal·2026
See all related articles

Related Experiment Video

Updated: Mar 6, 2026

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.4K

Cardiotoxicity Following Cancer Treatment.

G M Walls1, A R Lyon2, M T Harbinson3

  • 1The Royal Marsden Hospital NHS Foundation Trust, Fulham Road, London.

The Ulster Medical Journal
|March 17, 2017
PubMed
Summary
This summary is machine-generated.

Cancer survivors face increased risks of heart problems due to cancer treatments. Understanding and managing this cardiac toxicity is crucial for physicians caring for cancer patients.

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.5K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.3K

Related Experiment Videos

Last Updated: Mar 6, 2026

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.4K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.5K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.3K

Area of Science:

  • Oncology
  • Cardiology
  • Cancer Survivorship

Background:

  • Over 50% of individuals born after 1960 are projected to develop cancer.
  • Cancer cure rates have significantly improved over the past 30 years.
  • Increased cancer survivorship leads to a higher incidence of long-term treatment side effects.

Purpose of the Study:

  • To highlight the growing issue of cardiac toxicity in cancer survivors.
  • To emphasize the importance of managing cardiovascular adverse events associated with cancer therapy.
  • To inform physicians about the cardiac implications of cancer treatment.

Main Methods:

  • Review of current literature on cancer therapeutics and cardiac side effects.
  • Analysis of survivorship data and long-term health outcomes.
  • Clinical case discussions and expert consensus.

Main Results:

  • Cancer therapeutics can cause significant and potentially long-lasting cardiac toxicity.
  • Early detection and management of cardiac issues are vital for improving survivorship.
  • A multidisciplinary approach involving oncologists and cardiologists is beneficial.

Conclusions:

  • Physicians must be aware of the cardiac risks associated with cancer treatments.
  • Proactive cardiac monitoring and management are essential for cancer survivors.
  • Integrating cardiac care into oncology survivorship is a critical next step in patient management.